Programs
Clinical
Program

ExCellThera’s clinical program is currently focused on its most advanced technology, ECT-001 Cell Therapy.

Our vision is to make available for transplant, within 48 hours, our ECT-001 Cell Therapy cryo-preserved pre-expanded product for any patient in need.

MOST ADVANCED CLINICAL PROGRAM ECT-001 Cell Therapy 7 days Blood Unit UM171 Infusion 60+ Patients Dosed One-Time Treatment Blood Cancers Phase II Trials Orphan Drug (FDA, EMA) RMAT (FDA) Infusion 7 days UM171 Blood Unit ECT-001 Cell Therapy 60+ Patients Dosed One-Time Treatment Blood Cancers Phase II Trials Orphan Drug (FDA, EMA) RMAT (FDA)
Contact us
Programs
Ongoing
Developments

Our Total Cell Therapy concept combines ECT-001 technology with modular add-on treatments to address any residual diseases using dendritic vaccines, CAR Stem Cells or small molecules that leverage surplus ECT-001 expanded product.

We also have a number of other programs in our R&D pipeline.

Cell Therapy ECT-001 Cell Therapy expanded product Surplus Modular Add-On Therapy Dendritic vaccines CAR Stem Cells Small Molecules ECT-001 Add-On Therapy MODULAR ADD-ON THERAPY Advanced Usability Multiple patients per blood unit Ready-to-use pre-expanded units MODULAR ADD-ON THERAPY Cell Therapy ECT-001 Cell Therapy expanded product Surplus If relapse ECT-001 Add-On Therapy Modular Add-On Therapy Dendritic vaccines CAR Stem Cells Small Molecules Advanced Usability Ready-to-use pre-expanded units Multiple patients per blood unit
Contact us
Programs
R&D
Programs

ExCellThera has several R&D programs in its pipeline, including the development of gene enhancer therapies, active degraders (PROTAC) and other targeted therapies.

OTHER R&D PROGRAMS Other Targeted Therapies Gene Therapy Enhancer Active Degrader (PROTAC) OTHER R&D PROGRAMS Gene Therapy Enhancer Other Targeted Therapies Active Degrader (PROTAC)
Contact us
Programs
Clinical
Pipeline

ExCellThera is developing a pipeline of advanced cell therapies that are poised to challenge the current standard of care across various indications with unmet medical needs.

The company has a number of ongoing trials and R&D efforts at various stages of development. Link to Clinical Trials

AML/ALL/MDS Multiple Myeloma Sickle Cell Disease Discovery Pre- Clinical Phase I Phase 2 Phase 3 AML/ALL/MDS Multiple Myeloma Sickle Cell Disease Discovery Pre-Clinical Phase I Phase 2 Phase 3
Contact us
Programs
GREATER
Availability & Flexibility

ExCellThera’s ECT-001 technology renders more cord blood units avaliable to treat partients. Whereas only the largest 5% of units from a cord blood bank inventory can be used in treatments for adult patients (due to CD34 and TNC minimum dosage requirements), ECT-001 enables the potential use of over 90% of cord blood bank inventories.

In addition to providing a greater inventory of cord blood units available to select from for their patients, the ECT-001 technology also provides treating clinicians with greater flexibility in HLA matching and control over the administered T-cell dose

Smaller Units Units used in ECT-001 trials Larger Units
Contact us
Programs
Stem Cell Transplant
Standard
of Care
The current standard of care for hematopoietic stem cell transplants comes with a risk of various clinical complications for patients, including treatment related mortality, relapse and Graft versus Host Disease. Each stem cell source comes with its own pros and cons. ECT-001 combines the best of all worlds and is poised to challenge the standard of care.
TRM * Acute GvHD Engraftment Relapse * Mod./Sev. cGvHD * Lead Time Suitable CBUs Bone Marrow Peripheral Blood Unexpanded Cord Blood ECT-001 Treatment Related Mortality (TRM)* Acute Graft versus Host Disease Engraftment Failures/Delays Relapse* Moderate or Severe Chronic GvHD* Lead Time Suitable Cord Blood Units Bone Marrow Low Low Moderate High Long Low Peripheral Blood Low Low High Moderate Long Low Unexpanded Cord Blood Low Low Short High High High Low ECT-001 Low Low Low Very Low None Short High
Contact us
Programs
Clinical
Results
Phase I/II

The clinical results for ECT-001’s Phase I/II trial, on a high-risk patient population, have been exceedingly positive and challenge the current standard of care.

These results were published in
The Lancet Haematology in early 2020.

Standard of Care All patient profiles at 3 years 15-35% 25-40% 7-50% 10-35% 5% 21% 0% 64% TRM Treatment Related Mortality Relapse cGvHD Moderate to Severe GRFS GvHD & Relapse Free Survival ECT-001 >50% very high-risk patients at 35 months * After 3-year median follow-up. Phase I/II open-label study completed in June 2018, where 22 patients (>50% very high risk) suffering from AML, CML and NHL, received ECT-001-CB. Standard of Care All patient profiles at 3 years ECT-001 >50% very high-risk patients at 35 months 15-35% 25-40% 7-50% 10-35% 5% 21% 0% 64% TRM Treatment Related Mortality * After 3-year median follow-up. Phase I/II open-label study completed in June 2018, where 22 patients (>50% very high risk) suffering from AML, CML and NHL, received ECT-001-CB. Relapse cGvHD Moderate to Severe GRFS GvHD & Relapse Free Survival
Contact us